Penn R D, Paice J A
J Neurosurg. 1987 Aug;67(2):182-6. doi: 10.3171/jns.1987.67.2.0182.
Forty-three patients with intractable pain received intrathecal morphine delivered by implanted continuous-infusion (Infusaid) or programmable (Medtronic) devices. In 35 patients the pain was due to cancer, and eight patients had chronic nonmalignant pain. The origin of the nonmalignant pain included lumbar arachnoiditis, multiple sclerosis, severe osteoporosis resulting in a thoracic compression fracture, and intractable pain as a consequence of cancer therapy in individuals cured of their disease. Twenty-eight (80%) of the patients with cancer-related pain experienced excellent or good relief. Side effects were rare. Tolerance occurred infrequently and could be managed effectively. The results of this study support earlier studies on the application of chronic intrathecal morphine for intractable cancer pain. These findings also indicate that, in carefully selected patients, nonmalignant pain may be managed satisfactorily with this technique.
43例顽固性疼痛患者接受了通过植入式持续输注（Infusaid）或可编程（美敦力）装置给予的鞘内吗啡治疗。35例患者的疼痛由癌症引起，8例患者患有慢性非恶性疼痛。非恶性疼痛的病因包括腰椎蛛网膜炎、多发性硬化症、导致胸椎压缩性骨折的严重骨质疏松症，以及疾病已治愈的个体因癌症治疗而产生的顽固性疼痛。28例（80%）癌症相关疼痛患者的疼痛得到了显著或良好缓解。副作用很少见。耐受性很少出现，且能得到有效控制。本研究结果支持了早期关于慢性鞘内吗啡用于顽固性癌症疼痛的研究。这些发现还表明，在经过精心挑选的患者中，使用该技术可以令人满意地控制非恶性疼痛。
